ArticleNature2016
HER2 expression identifies dynamic functional states within circulating breast cancer cells.
Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03979339 (Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers), which is not on this map. Cited by 236 papers.
0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed
23.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers
Who cites it
236 citing papers in PubMed, 405 citations in OpenAlex.
- Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.Breast cancer research and treatment · 2024Trial
- First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.Investigational new drugs · 2020Trial
- Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.Breast cancer research : BCR · 2019Trial
- High-quantity capture of heterogeneous circulating tumor cellsMaterials today. Bio · 2026Article
- The immune phenotype of circulating tumor cells: from escape mechanisms to immunotherapy navigation.Biomarker research · 2026Review
- Mitochondrial transcript abundance in breast cancer circulating tumour cells may reflect both blood-derived transcripts and biological heterogeneity.Clinical & experimental metastasis · 2026Article
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- Ridge-assisted micro positioning of cells in a channel.Science advances · 2026Article
- Evolution of oncogene amplification across 86,000 cancer cell genomes.bioRxiv : the preprint server for biology · 2026Article
- Intratumor heterogeneity in human basal like breast cancer is revealed by single cell molecular subtyping.Communications medicine · 2026Article
- Automated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusion-weighted imaging.BMC cancer · 2025Article
- Minimal Residual Disease in Breast Cancer: Tumour Microenvironment Interactions, Detection Methods and Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Ridge-assisted Micro Positioning of Cells and Particles in a Microchannel.bioRxiv : the preprint server for biology · 2025Article
- Advances in biomonitoring technologies for women's health.Nature communications · 2025Review
- Liquid biopsy in breast cancer: Redefining precision medicine.The journal of liquid biopsy · 2025Review
- Intercellular signaling reinforces single-cell level phenotypic transitions and facilitates robust re-equilibrium of heterogeneous cancer cell populations.Cell communication and signaling : CCS · 2025Article
- Clinical applications of circulating tumor cells in metastasis and therapy.Journal of hematology & oncology · 2025Review
- Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.Cancer cell · 2025Review
- Mediating factors between autoimmune thyroiditis and breast cancer: a bidirectional Mendelian randomization study.Discover oncology · 2025Article
- CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
176 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
24 authors at 3 institutions in 1 country.
Nicole Vincent JordanMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Ben S WittnerMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Cyril BenesMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Matteo LigorioMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Yu ZhengMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Min YuMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Tilak K SundaresanMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Joseph A LicausiMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Rushil DesaiMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Ryan M O'KeefeMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Richard Y EbrightMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Myriam BoukhaliMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Srinjoy SilMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Maristela L OnozatoMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Anthony J IafrateMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Ravi KapurCenter for Bioengineering in Medicine and Shriners Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
Dennis SgroiMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
David T TingMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Mehmet TonerDepartment of Surgery, Harvard Medical School, Boston, Massachusetts 02114, USA.
Sridhar RamaswamyMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Wilhelm HaasMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Shyamala MaheswaranMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Daniel A HaberMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Harvard University · USMassachusetts General Hospital · USHoward Hughes Medical Institute · US
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MPoint-of care Microfluidics for Early Detection of CancerU01EB012493 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., TONER, MEHMET · 2010 to 2018
$19.6MDana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MTumor Cell Biology Training ProgramT32CA009361 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRAY, NATHANAEL SCHIANDER · 1985 to 2015
$8.9MModeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA129933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber · 2008 to 2026
$7.5MBIOLOGY OF THE OVARIAN FOLLICLE STEM CELLSF32CA009361 · NCI · CARNEGIE INSTITUTION OF WASHINGTON, D.C. · PI MARGOLIS, JONATHAN S · 1992 to 1994
–Howard Hughes Medical InstituteNCI NIH HHS F32 CA009361NCI NIH HHS K12 CA087723NCI NIH HHS R01 CA129933NCI NIH HHS T32 CA009361NIBIB NIH HHS U01 EB012493NIGMS NIH HHS T32 GM007753Wellcome Trust
Abstract
Circulating tumour cells in women with advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer acquire a HER2-positive subpopulation after multiple courses of therapy. In contrast to HER2-amplified primary breast cancer, which is highly sensitive to HER2-targeted therapy, the clinical significance of acquired HER2 heterogeneity during the evolution of metastatic breast cancer is unknown. Here we analyse circulating tumour cells from 19 women with ER
Indexed as
Breast NeoplasmsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoplastic Cells, CirculatingPhenotypeReceptor, Notch1Signal TransductionERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesNOTCH1 protein, humanReceptor, Notch1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03979339ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.